Clinical Trial

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this Phase II single-arm study is to prospectively explore the efficacy of chemotherapy plus EGFR inhibitors in patients with liver metastases from total wild-type colorectal cancer with ctDNA superselective negative genes.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06490913
Lead Sponsor Fujian Cancer Hospital
Conditions Liver Metastases of Colorectal Cancer
Enrollment 33 participants
Start Date 2024-11-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-08